In Silico Prioritization of GWAS-Derived 3′ UTR MicroRNA-Binding Variants at Colorectal Cancer Risk Loci Detected in Hispanic Patients from the All of Us Research Program
This study utilizes the All of Us Research Program to identify and prioritize three ancestry-matched, non-coding microRNA-binding variants in the 3′ UTRs of *DCBLD2*, *GREM1*, and *SMC1B* that likely drive colorectal cancer risk in Hispanic patients by disrupting miRNA-mediated repression and promoting gene overexpression.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer often begins with a simple mistake in the genetic code, a tiny typo in the instruction manual that tells our cells how to grow. For decades, scientists have focused on finding these typos in the parts of the code that directly build proteins, the workhorses of the body. However, a vast amount of our genetic material does not build proteins at all; instead, it acts as a control panel, telling those proteins when to start, when to stop, and how much to make. One of the most important control mechanisms involves short strands of genetic material called microRNAs. These molecules act like dimmer switches, binding to specific spots on a gene's message to lower its volume or turn it off completely. When a genetic typo occurs right at the spot where a microRNA is supposed to attach, the switch can break. The gene might then stay stuck in the "on" position, producing too much of a protein that drives uncontrolled cell growth. This mechanism is particularly relevant for colorectal cancer, a disease that kills more people than almost any other, yet the genetic maps used to understand it have historically been drawn almost entirely from people of European descent. This leaves a massive gap in our knowledge for Hispanic and Latino populations, who face unique risks and often develop the disease at younger ages, because the genetic switches that matter to them may look different than those found in European studies.
A team of researchers at the University of Texas at El Paso set out to fill this gap by building a new kind of genetic map specifically for Hispanic patients. They started with a list of known risk spots for colorectal cancer, gathered from global studies, and asked a simple but critical question: do these spots exist in the Hispanic community, and do they break the same genetic switches? To answer this, they turned to the All of Us Research Program, a massive national effort to gather health data from a diverse cross-section of Americans. They identified 453 Hispanic individuals with colorectal cancer within this database and checked their DNA against the known risk spots. This step was crucial because a risk variant found in one population might be rare or completely absent in another. Once they confirmed which variants were actually present in their Hispanic cohort, they used a specialized method to find other genetic markers that travel closely with these variants in people of mixed American ancestry, ensuring they did not miss the true cause just because the original marker was slightly different.
The researchers then focused their attention on the 3' untranslated regions of genes, which are the tail ends of genetic messages where microRNAs typically attach to regulate protein levels. They ran computer simulations to see if the specific genetic variations found in their Hispanic patients would change how well a microRNA could grab onto the gene. Imagine a key trying to fit into a lock; if the genetic typo changes the shape of the lock, the key no longer fits, and the door stays open. The team found that out of dozens of candidates, nineteen variants across nine different genes had the potential to disrupt this binding. However, not every disruption leads to cancer. To find the most dangerous ones, the researchers applied a strict set of filters. They looked for genes that were already known to be overactive in tumors, checked to see if the overactivity was caused by the broken microRNA switch rather than other factors like chemical tags on the DNA, and verified that high levels of these genes were linked to poorer survival rates for patients.
This rigorous process narrowed the field down to three specific genes: DCBLD2, GREM1, and SMC1B. For each of these, the researchers found a clear pattern. In the healthy state, a microRNA binds tightly to the gene's tail end, keeping its production in check. In the patients with the specific risk variant, that binding site is broken. The microRNA can no longer attach, and the gene is free to produce excessive amounts of protein. For DCBLD2 and GREM1, the evidence was particularly strong: the risk variant completely destroyed the binding site, the genes were found in high quantities in tumor tissue, and this overproduction was not caused by other regulatory mechanisms like DNA methylation. Instead, it appeared to be a direct result of the broken microRNA switch. For the third gene, SMC1B, the situation was slightly more complex, involving both the broken switch and other regulatory factors, but the loss of microRNA control remained a key driver. The study also confirmed that patients with high levels of these three genes tended to have shorter survival times, suggesting that these genetic errors are not just bystanders but active contributors to the disease's severity.
The significance of this work lies in its approach. By anchoring their discovery process in the genetic reality of the Hispanic population, the researchers avoided the pitfalls of applying European-based models to a different group. They demonstrated that ancestry matters not just for finding risk spots, but for understanding how those spots function. The study suggests that for these three genes, the path to cancer in Hispanic patients may involve a specific type of genetic error where the body's natural volume controls are silenced. While the researchers emphasize that these findings are currently based on computer models and require further laboratory testing to confirm the biological mechanisms, the results provide a clear, testable hypothesis for why certain individuals are more susceptible to colorectal cancer. It highlights a path forward for more equitable genomic medicine, where the tools used to understand disease are as diverse as the people they are meant to protect, ensuring that the benefits of genetic discovery reach everyone, not just a select few.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.